肿瘤转移大致有经脏器表面间的接触和向体腔内的游移而进行的播散性转移、经淋巴系统的转移及血原性转移这三种途径,其中后者被认为是发生肿瘤远距转移的主要原因。鉴于血原性转移须经下列一系列历程即在原发巢的血管新生、自原发巢剥离、浸润周边组织、侵入血管内、在血管内生存和循环、通过对靶的脏器内血管壁的附着或栓塞而固着、破坏血管壁、浸润组织内部并再次增殖等方能完成,故若能设法阻止其中任一步骤的实现,就可产生抗肿瘤转移效果。本文就目前尚处于研究阶段的抗肿瘤转移药物的开发原 Tumor metastasis generally by the contact between the organ surface and to the body cavity of the migration of the disseminated metastasis by the lymphatic system and the transfer of hematogenous these three ways, of which the latter is considered the occurrence of tumor distance The main reason for the transfer. In view of hematogenous metastasis through a series of processes that is in the neovascularization of the neovascularization, peel from the original nest, infiltration of peripheral tissue, invasion of blood vessels, survival and circulation in the blood vessels, through the target vessel wall Of the attachment or embolism and fixation, destruction of the vessel wall, infiltration of tissue and proliferation again to complete, so if you can try to prevent any one of the steps to achieve anti-tumor metastatic effect can be produced. This article is currently still in the research stage of anti-tumor drug development